Computational Design of Peptide Masks Enables Conditionally Active Miniprotein Therapeutics
By
Benjamí Oller-Salvia
Summary
This article presents a novel computational approach for designing conditionally active miniprotein binders through de novo peptide masks. The method addresses a key challenge in protein therapeutics: targets are often expressed in both diseased and healthy tissues, causing dose-limiting toxicities. The researchers engineered peptide masks that block the binding interface of miniproteins until they are cleaved by disease-associated proteases, enabling site-specific activation. The paper details the computational design pipeline, experimental validation, and demonstrates successful application across multiple therapeutic targets. This represents a significant advance in creating safer, more targeted protein therapeutics with improved therapeutic indices.
Source
Key quotes
· 3 pulledProtein therapeutics have transformed the treatment of diseases ranging from cancer to immune disorders, largely owing to their high target selectivity.
Yet many therapeutic targets are expressed not only at diseased sites but also in healthy tissues, frequently leading to dose-limiting toxicities.
A compelling strategy to improve the therapeutic index is to engineer conditionally active biologics that remain inert systemically and are activated only at the site of disease.
You might also wanna read
De novo design of peptides localizing at the interface of biomolecular condensates
De novo design of miniproteins targeting GPCRs
Global protein-ligand binding affinity profiling via photocatalytic labeling

PEP-EDIT: A Web Server for 3D Generation and Interactive Editing of Complex Peptide Structures
This article presents PEP-EDIT, a web server tool designed for generating and interactively editing 3D structures of complex peptides. It ad
Systematic discovery of motif-based interactions of the auxiliary domains of USP family deubiquitinases

AI Advances in Drug Discovery: From Data Integration to Dual-Action Cancer Drug Design
The article discusses recent advancements in AI-driven drug discovery, highlighting two key developments: 1) Analytica 2026, an event focuse

Comments
Sign in to join the conversation.
No comments yet. Be the first.